TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant

Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Nov 7, 2018

Keywords

ClinConnect Summary

This clinical trial is looking at different ways to manage pain after kidney transplant surgery. The researchers want to compare two methods: one involves using a continuous infusion of a pain-relieving medication called ropivacaine through special catheters placed in the abdomen, while the other method uses a single injection of a longer-lasting pain relief medication called liposomal bupivacaine. The goal is to find out which method works better for controlling pain after the surgery.

To participate in this study, you need to be at least 18 years old and have received a kidney transplant. Unfortunately, if you are pregnant, have certain medical conditions, or are taking high doses of other pain medications, you may not be eligible. If you join the study, you will receive one of the two pain management methods and be monitored closely for your comfort and recovery. This trial is currently recruiting participants, so if you or someone you know might be interested, it’s a good idea to talk to your healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients ages 18 years or older
• • Renal Transplant Recipients
• Exclusion Criteria:
• • Patients less than 18 years of age
• • Pregnant Women
• • Prisoners
• • Opioid Tolerant Patients taking more than 30 mg/day of oral morphine equivalent analgesia
• • Patients on Systemic anti coagulation
• • Patients unable to provide consent
• • Hypersensitivity to amide-type local anesthetic or any component of the drug formula